QLT to Acquire InSite Vision in All-Stock Deal
QLT has signed a definitive agreement to buy InSite Vision for $0.178 per share in an all-stock deal. QLT says the merger will create a diversified, pure-play, late-stage ophthalmic pharmaceutical company well equipped to advance QLT’s existing phase 3–ready retinoid program and the multiple additional late-stage assets...